Apoorva Sarode
Overview
Explore the profile of Apoorva Sarode including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
328
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barr K, Ohnsorg M, Liberman L, Corcoran L, Sarode A, Nagapudi K, et al.
Bioconjug Chem
. 2024 Mar;
35(4):499-516.
PMID: 38546823
Nanodroplet formation is important to achieve supersaturation of active pharmaceutical ingredients (APIs) in an amorphous solid dispersion. The aim of the current study was to explore how polymer composition, architecture,...
2.
OBrien Laramy M, Costa A, Cebrero Y, Joseph J, Sarode A, Zang N, et al.
Mol Pharm
. 2023 Jul;
20(8):4285-4296.
PMID: 37462906
The recent clinical and commercial success of lipid nanoparticles (LNPs) for nucleic acid delivery has incentivized the development of new technologies to manufacture LNPs. As new technologies emerge, researchers must...
3.
Hammel M, Fan Y, Sarode A, Byrnes A, Zang N, Kou P, et al.
ACS Nano
. 2023 Jun;
17(12):11454-11465.
PMID: 37279108
With three FDA-approved products, lipid nanoparticles (LNPs) are under intensive development for delivering wide-ranging nucleic acid therapeutics. A significant challenge for LNP development is insufficient understanding of structure-activity relationship (SAR)....
4.
Pratsinis A, Fan Y, Portmann M, Hammel M, Kou P, Sarode A, et al.
Int J Pharm
. 2023 Mar;
637:122874.
PMID: 36948476
Lipid nanoparticles (LNPs) have been widely investigated for nucleic acid therapeutic delivery, and demonstrated their potential in enabling new mRNA vaccines. LNPs are usually formulated with multi-lipid components and the...
5.
Dasgupta A, Sun T, Palomba R, Rama E, Zhang Y, Power C, et al.
Proc Natl Acad Sci U S A
. 2023 Mar;
120(13):e2218847120.
PMID: 36940339
Surface tension provides microbubbles (MB) with a perfect spherical shape. Here, we demonstrate that MB can be engineered to be nonspherical, endowing them with unique features for biomedical applications. Anisotropic...
6.
Sun T, Krishnan V, Pan D, Filippov S, Ravid S, Sarode A, et al.
Bioeng Transl Med
. 2023 Mar;
8(2):e10408.
PMID: 36925708
Effective chemotherapy delivery for glioblastoma multiforme (GBM) is limited by drug transport across the blood-brain barrier and poor efficacy of single agents. Polymer-drug conjugates can be used to deliver drug...
7.
Sarode A, Fan Y, Byrnes A, Hammel M, Hura G, Fu Y, et al.
Nanoscale Adv
. 2022 Sep;
4(9):2107-2123.
PMID: 36133441
Lipid nanoparticles (LNPs) are gaining traction in the field of nucleic acid delivery following the success of two mRNA vaccines against COVID-19. As one of the constituent lipids on LNP...
8.
Shukla S, Sarode A, Wang X, Mitragotri S, Gupta V
Biomater Adv
. 2022 Aug;
137:212850.
PMID: 35929278
Therapeutic drug delivery is known to be influenced by interplay between various design parameters of delivery carriers which influence the drug uptake efficiency and subsequently the effectiveness of treatment. Amongst,...
9.
Gao Y, Vogus D, Zhao Z, He W, Krishnan V, Kim J, et al.
Bioeng Transl Med
. 2022 Feb;
7(1):e10245.
PMID: 35111947
Antiproliferative chemotherapeutic agents offer a potential effective treatment for inflammatory arthritis. However, their clinical application is limited by high systemic toxicity, low joint bioavailability as well as formulation challenges. Here,...
10.
Shukla S, Sarode A, Kanabar D, Muth A, Kunda N, Mitragotri S, et al.
Mater Sci Eng C Mater Biol Appl
. 2021 Sep;
128:112324.
PMID: 34474875
Pulmonary drug delivery is governed by several biophysical parameters of delivery carriers, such as particle size, shape, density, charge, and surface modifications. Although much attention has been given to other...